The dual role of leukotrienes in the tumor microenvironment: balancing pro-tumorigenic and anti-tumor immunity. (PubMed, Cancer Biol Ther) - Jun 24, 2026 - "In preclinical models, pharmacological agents including montelukast, zileuton, and FLAP antagonists suppress tumor growth, and restore apoptotic signaling; current clinical evidence remains largely observational and pharmacoepidemiologic. Targeting this pathway represents a promising avenue in oncology, with potential to enhance precision medicine through biomarker-guided patient stratification. Further clinical validation is warranted to translate these findings into therapeutic benefit."
Biomarker • Journal • Review • Immune Modulation • Immunology • Oncology • HIF1A
|
|
Andrew Thake; Keith Sacco; Maria Caruso; Sebastián Fernandez-Bussy
|